Tag: pharma policy

Future Trends: AI, RWE and New Business Models in M&A and Licensing Effects on Trials The landscape of clinical research is rapidly evolving, influenced by technological advancements, novel regulatory frameworks, and innovative business models. As we delve into the future of clinical trials, it is vital that clinical operations, regulatory affairs, and medical affairs professionals…

Read More “Future Trends: AI, RWE and New Business Models in M&A and Licensing Effects on Trials” »

Digital Tools and Analytics to Forecast and Monitor M&A and Licensing Effects on Trials The landscape of clinical trials is continually evolving, particularly in the context of mergers and acquisitions (M&A) and licensing agreements that significantly impact how clinical research is conducted. For professionals engaged in clinical operations, regulatory affairs, and medical affairs, understanding the…

Read More “Digital Tools and Analytics to Forecast and Monitor M&A and Licensing Effects on Trials” »

Risk Scenarios and Sensitivity Analyses for M&A and Licensing Effects on Trials Risk Scenarios and Sensitivity Analyses for M&A and Licensing Effects on Trials In the complex landscape of clinical trials, the implications of mergers and acquisitions (M&A) and licensing arrangements are profound. As the biopharmaceutical industry continues to evolve, understanding the risks associated with…

Read More “Risk Scenarios and Sensitivity Analyses for M&A and Licensing Effects on Trials” »

Regulatory and Policy Shifts Reshaping M&A and Licensing Effects on Trials in the US, EU and UK Regulatory and Policy Shifts Reshaping M&A and Licensing Effects on Trials in the US, EU and UK The landscape of clinical trials is continuously evolving, driven by various regulatory and policy shifts. These changes are particularly significant in…

Read More “Regulatory and Policy Shifts Reshaping M&A and Licensing Effects on Trials in the US, EU and UK” »

Using Real-World Data to Inform M&A and Licensing Effects on Trials Decisions Using Real-World Data to Inform M&A and Licensing Effects on Trials Decisions The landscape of clinical research is constantly evolving, particularly in the context of mergers and acquisitions (M&A) and licensing agreements within the pharmaceutical and biotechnology sectors. The use of real-world data…

Read More “Using Real-World Data to Inform M&A and Licensing Effects on Trials Decisions” »

Governance Models and Cross-Functional Ownership for M&A and Licensing Effects on Trials Governance Models and Cross-Functional Ownership for M&A and Licensing Effects on Trials The impact of mergers and acquisitions (M&A) and licensing agreements on clinical trials is significant and multifaceted. As the biopharmaceutical landscape evolves, understanding the governance models and cross-functional ownership that influence…

Read More “Governance Models and Cross-Functional Ownership for M&A and Licensing Effects on Trials” »

M&A and Licensing Effects on Trials: What Clinical Leaders Need to Know Now The dynamics of mergers and acquisitions (M&A) and licensing agreements within the pharmaceutical and biotechnology industries significantly influence clinical trial operations. Understanding these effects is crucial for clinical operations, regulatory affairs, and medical affairs professionals who navigate the complexities of drug development….

Read More “M&A and Licensing Effects on Trials: What Clinical Leaders Need to Know Now” »

How to Model M&A and Licensing Effects on Trials for Global Study Portfolios The dynamics of mergers and acquisitions (M&A) and licensing deals in the biopharmaceutical industry have far-reaching implications on clinical trials, particularly in a global context. The ability to effectively model these effects is crucial for clinical operations, regulatory affairs, and medical affairs…

Read More “How to Model M&A and Licensing Effects on Trials for Global Study Portfolios” »

M&A and Licensing Effects on Trials in Practice: Benchmarks, Case Studies and Playbooks The landscape of clinical research is constantly evolving, with mergers and acquisitions (M&A) and licensing agreements shaping the way clinical trials are conducted. This article provides a comprehensive view of how M&A and licensing impact clinical trials in practice, including benchmarks and…

Read More “M&A and Licensing Effects on Trials in Practice: Benchmarks, Case Studies and Playbooks” »

High-Impact M&A and Licensing Effects on Trials Strategies That Protect Trial Timelines and Margins High-Impact M&A and Licensing Effects on Trials Strategies That Protect Trial Timelines and Margins The landscape of clinical trials is evolving rapidly, influenced significantly by mergers, acquisitions (M&A), and licensing agreements. These high-impact business strategies can profoundly affect trial planning, execution,…

Read More “High-Impact M&A and Licensing Effects on Trials Strategies That Protect Trial Timelines and Margins” »